What did @peptidephixofficial1 actually say?
The creator pitched GHK-Cu as a peptide capable of addressing fine lines, hollow under-eyes, dark circles, hyperpigmentation, and skin texture. They laid out a specific injectable protocol: a loading phase of 10 to 20 units daily for weeks one through four, followed by a maintenance phase of 10 units daily through weeks four to twelve. They also claimed that cycling the peptide prevents skin adaptation and that breaking doses into Monday, Wednesday, Friday schedules is acceptable based on personal tolerance.
That is a fairly detailed dosing framework for a peptide that, in the United States, is not FDA-approved for any injectable cosmetic indication. Worth keeping that context front of mind before anything else.
Does the science back this up?
Partially, but the research base is much thinner than this video implies. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) does have real supporting data, mostly in topical and in vitro settings, not injectable human trials.
Pickart and Margolina (2018, Cosmetics) reviewed decades of GHK-Cu research and found consistent evidence that the peptide stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinase activity, and promotes skin repair in cell culture and animal models. Finkley et al. (1989, Journal of Geriatric Dermatology) found topical GHK-Cu improved skin laxity and thickness in a small human trial. Those are real findings.
What the science does not have is a well-powered, randomized controlled trial on subcutaneous injectable GHK-Cu in humans for cosmetic skin endpoints. The loading-versus-maintenance cycle framing, and the specific unit dosages given here, are not drawn from published clinical literature. They appear to be community-derived protocols circulating in peptide forums.
What did they get wrong (or right)?
Credit where it is due: the general biology the creator describes is not made up. Saying GHK-Cu helps regulate collagen and elastin and supports skin barrier repair is consistent with what the in vitro and topical literature shows. The recommendation to cycle rather than run indefinitely is a reasonable harm-reduction posture, even if the specific rationale about skin adaptation is unverified.
What they got wrong, or at minimum oversold, is the confidence of the framing. Saying GHK-Cu will address hollow under-eyes and dark circles treats a peptide with limited topical human data as if it were a proven injectable therapy. Dark circles in particular have multiple causes, including vascular pooling, fat loss, and pigmentation, and there is no published injectable GHK-Cu trial for any of them.
More importantly, the specific dosing units are presented without disclosing that injectable GHK-Cu is an unregulated compounded preparation with no standardized concentration across suppliers. Telling viewers to pull a specific unit count without that context is genuinely problematic. The reconstitution instruction, "toot it with two ml of backwater," references bacteriostatic water, but the casual delivery obscures that reconstitution errors carry real risk.
What should you actually know?
GHK-Cu is a naturally occurring copper peptide found in human plasma, and it does appear to play a role in wound healing and skin remodeling based on existing science. That is not nothing. But there is a large gap between a peptide showing activity in lab conditions and it being a proven injectable anti-aging therapy with defined dosing protocols.
Injectable GHK-Cu in the United States is available only through compounding pharmacies and sits in a regulatory gray zone. The FDA has not approved it for any injectable indication. Concentration and purity vary by supplier, which means unit-based dosing advice from a social media video is not transferable across products.
If you are considering GHK-Cu, the most evidence-supported delivery route is topical. For injectable use, that conversation belongs with a licensed prescriber who can evaluate your full health picture, not a TikTok protocol. The 8 to 12 week cycle idea is not dangerous on its face, but it is also not clinically validated.